only up to the fourth passaging of RK 13 cell line exclusively the MEM medium was used for further replications. Using the latter medium it was possible to obtain the cell monolayers suitable both for virus passaging and for the actual vaccine preparation. As the medium for culture maintenance after the infection of cell monolayer the Earle as well as MEM media were used, none of them containing bovine serum.
Culture passaging of RK 13 cell line
The subpassages of RK 13 cell line were prepared from well developed cultures preserved in Roux bottles, usualy after a week's intervals. After the removal of medium the culture was washed with the versen-trypsin solution at 37°C, then rinsed and immersed for 5 minutes into versen--trypsin. After this time the supernatant was removed and the bottles were turned so that their culture containing parts were facing up. In this arrangement they were placed into a thermostat at 37°C for 20 minutes. When the residual versen-trypsin was decanted the free cells were mixed to form a suspension in the MEM growth medium. Out of one Roux bottle contents usually 3 vessels of the same culture volume were obtained.
Virus
The starting strain for the adaptation to the RK 13 cell line the commercial vaccine against rabbit myxomatosis was selected. This vaccine is prepared from SFV replicated on rabbits and it has been commercially produced by Bioveta at Ivanovice na Hane,
Challenge virus
To check the immunity after the SFV application the dose corresponding to 1000 ID 50 of virulent myxomatosis virus was applied upon carrying out the preliminary experiments (J efabek unpublished results) which revealed no difference in the course of myxomatosis after the challenge by 10 2-10 5 ID 50 of virulent myxomatosis virus in rabbits. The overall challenge dose (1000 ID 5o ) was administered into both conjunctival sacs (one drop each), the rest (up to 1 ml) being applied subcutaneously.
Rabbits
To make sure that both vaccine and the virus passaged on RK 13 cell line are safe and efficient, healthy animals weighing 1.5 -2.0 kg were selected out of breeds where no previous vaccination against myxomatosis was carried out.
Procedure of virus passaging
Three-day-old cell monolayers of RK 13 cell line were used for the infection by virus. These monolayers were prepared in two ways: 1. The same procedure as that applied for passaging cultures of the RK 13 cell line 2. The same as above, the only difference being the use of Earle medium. This second possibility may be employed only for the preparation of culture which is to be used for the infection by virus. As already mentioned the Earle medium cannot be used for a routine passaging of RK 13 cell line cultures.
Vi rus passaging
The developed monolayer of RK 13 cells was infected by the storage virus (i. e. the suspension of virus from the previous passage) and after a 30 minutes' adsorption the contents of Roux bottle were filled with the nine-fold amount of medium (3 em" of virus and 27 ern" of medium were applied in the case of 300 em" bottles, 5 em" of virus and 45 ern" of medium for 500 ern" bottles and 10 em" of virus and 90 ern" of medium for 1000 ern" bottles). In case that the RK 13 line cells were cultivated prior to infection in the MEM growth medium, .the maintenance MEM medium was added. When the Earle medium was used for replication of. cells to be infected, the medium for maintenance according to Earle was also used. The adaptation of virus as well as its other passage on the RK 13 cell line was thus carried out parallely in MEM and Earle medium.
After filling up the medium the cultivation of the virus proceeded in a stationary manner at 37°C. When a significant cytopathic effect occurred (4th post -infection day) on the infected cells the latter were subjected to three freeze and thaw cycles. The suspensions obtained in this way represented the virus which was used for further passage. Efficiency and safety were verified in rabbits with the tenth and twentieth passage.
The vaccine preparation
The virus obtained from the tenth passage of RK 13 cell line was used for the actual vaccine preparation. Procedures of monolayer preparation and infection were identical with that of virus passage. After three freeze -thaw cycles the contents of individual Roux bottles were joined and the suspension thus obtained was stored at -20°C. Upon thawing, the suspension was mixed with the liquid lyophilic medium (0.5 ml of medium per 1 ml of suspension). The composition of medium was following: gelatine for bacteriology 300 g; sucrase 450 g; Na 2 H P0 4.12H 2 0 22.92 g; KH 2 P0 4 2.92 g; redistilled water 6000 ern", After the lyophilization and the sterility control tests were carried out establishing vaccine efficiency and safety. Invariably 6 em" were taken for lyophilization; these contained 4 ern" of virus suspension and 2 em" of lyophilic medium. Twenty vaccination doses were obtained upon. dilution of the lyophilizate with 20 em" of diluent. The· latter was either MEM and Earle medium, or buffered saline.
The efficiency and safety of vaccine were tested according to procedure adopted in Czechoslovakia for rabbit myxomatosis vaccine prepared from SFV replicated in rabbits.
After the control tests had been completed the production of the lyophilized vaccine has started up under the commercial name 8FT rabbit myxomatosis vaccine (8FT standing for Shope Fibroma virus replicated in Tissue cultures).
Safety test
Four experimental rabbits were observed for health status upon application of vaccine.
Procedure Rabbits with shaved backs were employed. Each animal was given 3 em" of commercial vaccine· intradermally by 12 injections a 0.25 em", Another two animals were given subcutaneous dose (3 em" each) applied on two separate sites (behind shoulder blade).
Evaluation of the test
The experimental animals are observed for 21 days. In intradermally inoculated animals pea-or bean-sized fibroma must develop at the site of application of vaccine but no generalization of fibromatosis may occur. Subcutaneously vaccinated animals must not exhibit general fibromatosis. or more serious local changes.
A small local fibroma occurring at the site of application is not considered serious. It is usually absorbed without detrimental effects before the end of observation period.
Apart from the above -mentioned test the safety of vaccine was checked by the subcutaneous. ·application of vaccine to young animals after weaning.
During the safety and efficiency testing of SFT vaccine in rabbits also the pure culture RK 13, containing no SFV, was inoculated intradermally (similarly to procedure applied for the virus titration). Two rabbits were given the suspension in MEM while in the other two cases the Earle medium was used. No reaction was observed upon the intradermal application. Upon challenge the animals developed myxomatosis and died.
The test of vaccine efficiency and of the passaged virus was made by determining ID50 according to R e e d and M u e n c h (1938) after the titration on rabbits. Moreover, challenge followed upon the application of passaged virus and one vaccination dose, respectively. The titres of virus in individual passages and in the prepared vaccine were compared with that of virus (vaccine) replicated in classical way in rabbit skin.
Virus titration
The titrations of harvested virus and lyophilized vaccine were always carried out by intradermal testing on the shaved backs of two experimental animals. Each rabbit was given 0.25 ern" of the undiluted vaccine or virus suspension. Moreover, corresponding dilutions down to 10 -5 were administered. Each dilution was applied by eight injections at the rate of 0.25 em", The reaction was evaluated from 6th to 12th day after the application. The size of developed fibromas was measured. The skin thickness was subtracted from the observed value in mm. The increase in thickness of 1 mm and more was considered positive for the calculation of 10 50 • Comparing 10 50 of individual virus passages or vaccines it was possible, according to titres, to evaluate their efficiency but the experimental values did not quite reflect the intensity of reaction of individual tests. Therefore a complementary criterion was adopted and referred to as overall reaction number (ORN) which represents an average of all daily sums (from 6th to 12th day) of all thickness increases in mm (size of fibromas) upon the application of individual dilutions of the virus being studied. The comparison of ORN corresponding to individual passages or vaccines contributes to a better comparison of their effectiveness.
The determination of protective doses in one vaccination dose (PD 50 ) Although the comparison of ID so and ORN of individual passages of virus or vaccines enables to compare their relative effectiveness, the immunogenic effect of the vaccination dose is not sufficiently expressed i. e. it is not known how many protective doses are present in one vaccination Table 1 Average logarithms of ID58 and average ORN of in cell cultures passaged Shope Fibroma Virus and prepared SFT vaccine Earle medium without serum MEM medium without serum buffered saline titration of virus used for the vaccine preparation before lyophilization titration of the lyophilized vaccine lyophilizate diluted to original volume with distilled water, further dilution effected by Eo medium titration of vaccine 24 hours after dilution, diluted vaccine stored at· +-4 "C Table 2 Safety and effectiveness of the passaged virus and the SFT vaccine dose. Therefore the number of protective doses (PD 00) was determined by means of titration on rabbits. To determine their value the calculation by Reed and Muench (1938) was employed. The lyophilized virus suspension was diluted to the original volume (= 10°) with redistilled water used for the preparation of tissue culture media. Further dilution was effected using the Earle medium for culture maintenance. The groups of experimental animals were given the individual dilutions of vaccine, the dose being 1 em" each. After 19 days of application the rabbits were infected with 1000 ID 50 of virulent myxomatosis virus. After the challenge the rabbits were observed for 6 weeks. Two standpoints were considered for the determination of PD 50 : 1. Only those animals were considered to be surviving for the determination of PD so which exhibited no reaction upon the challenge; 2. As surviving animals also those were considered which developed a reaction at the site of inoculation (primary myxoma) or temporary myxomatosis (benign myxomatosis).
The test of effectiveness by challenges of vaccinated rabbits at various time intervals after a single vaccination and after vaccination followed by revaccination
The vaccination dose of 1 em" was always used for both the vaccination and revaccination of rabbits. The revaccination was done 25th day after the first vaccination. The challenge was effected at various times after vaccination (revaccination) using the usual dose of myxomatous virus; the rabbits were then observed for 21 days.
In all tests of effectiveness of passaged SFV and of the vaccine prepared from it always two control rabbits were infected by the same challenge dose which upon challenge developed myxo . . . . matosis and died or were killed. Table 1 indicates that when compared with the original virus titre the titres were lower by 0.5-0.9 logs and that the ORN is not always directly dependent on log ID so • It is further obvious that the maintenance medium Eo is suitable for virus replication as well as a diluent of lyophilized vaccine. This fact is important from the economical point of view as well. Also buffered saline can be used for dilutions. The decrease of diluted vaccine effectiveness did not occur during 24 hours if both maintenance medium Eo and buffered saline were used. It is also evident from the Table that during passaging neither log ID so decrease nor ORN decrease occurred. Moreover, none of the followed values was negatively influenced by the lyophilization.
Results

Titration of passaged virus and of prepared vaccine
Assay of safety and of effectiveness of passaged virus and prepared vaccine Upon the subcutaneous application of various doses of passaged virus and prepared vaccine no postvaccination reaction was observed (Table 2) . Upon intradermal inoculation only fibromas at the inoculation site occurred. All rabbits, which had been challenged by virulent myxomatous virus, on the 9th-11th day after the subcutaneous application of passaged virus or vaccine, survived without reaction. Although no groups of the same number of experimental rabbits were used it is evident from Table 2 that no difference was found when two different diluents were used, i. e. Earle maintenance medium and buffered saline.
Apart from the results presented in Table 2 the safety and effectiveness oJ prepared vaccine were tested on young animals from two not vaccinated females.
From one mother three young rabbits were vaccinated immediately after weaning at the age of 23 days by the dose of 1 em" of diluted lyophilized vaccine (determined vaccination dose). No postvaccination reaction was observed. On the 45th day after vaccination the rabbits were infected by 1000 ID so of virulent myxomatous virus. Apart from a slight temporary infiltration at the inoculation site in two rabbits no further symptoms of the disease were noted.
From the other female rabbit two youngs aged 29 days (also immediately after weaning) were each vaccinated by a 3 em" dose of diluted lyophilized vaccine, this dose being triple of that used in the previous experiment. No reaction after the vaccination was observed. Challenge carried out 34th day after the vaccination did not induce any reaction except a slight temporary infiltration at the inoculation site in one rabbit.
Number of protection doses (PD so) in 1 em" of SFT vaccine
To determine PD 50 the SFT vaccine containing 103·~IDso/0.25 em" oflyophilized virus suspension, as found by titration on rabbits (see Table 1 ) was used.
Data to be used for the PDs:l calculation are presented in Table 3 . Since the commercial SFT vaccine consists of lyophilizate (equal to 4 em" of virus suspension and 2 em" of lyophilic medium) which is diluted by 20 em" of diluent prior to vaccination, 1 em" of diluted vaccine, that is one vaccination dose, contains 12.6 -400 PD so (4 X 63.1 === 252.4: 20 === 12.6; 4 X 2000 === 8000: 20 === 400). Table 3 Determination of PD so in 1 ern" of 8FT vaccine
Dilution
Number of rabbits a) Reaction to challenge The immunity duration in rabbits with single vaccination and in rabbits vaccinated and revaccinated by the same SFT vaccine dos e on the 25th, day after the first vaccination The result of immunity duration studies after a single vaccination are given in Table 4 . Up to the 84th day after a single vaccination the rabbits did not react upon challenge by virulent myxomatosis virus. In rabbits infected within a longer time interval after the vaccination the reaction induced by challenge was more distinct and apart from myxomatosis with benign course a typical myxomatosis with subsequent death developed.
The results of immunity duration studies after vaccination followed by subsequent revaccination are summarized in Table 5 . It is evident that up to the 121st Table 4 The immunity of rabbits vaccinated subcutaneously using 1 em 3 of 8FT Number of rabbits Challenge 1000 ID no effect, only local temporary reaction at the inoculation site of myxomatous virus BN -only temporary increased breathing and congestion of conjuctiva BM myxomatosis reaction followed by a subsequent recovery recovery (benign course of myxomatosis) M myxomatosis with a typical course, animal died or was killed Table 5 Immunity of rabbits subcutaneously vaccinated and revaccinated with 1 em" of 8FT vaccine 25th day after the first vaccination day after revaccination all rabbits survived the challenge without a marked reaction. The challenges effected from 158th to 228th day (no .experiments with longer period have been conducted) after the revaccination 75-100 % of rabbits survived without more distinct reaction.
Comparison of data presented in Table 4 and 5 shows that better immunity is obtained in rabbits vaccinated and revaccinated.
Discussion
It follows from hitherto available data on immunoprophylaxis of myxomatosis that no vaccine exists guaranteing a long-lasting immunity after single vaccination or after vaccination followed by revaccination in a vaccinated rabbit population. This fact is important mainly for breeding animals where vaccination scheme providing a satisfactory immunity has to be chosen for a period of myxomatosis peak occurrence.
Present results show that the SFT vaccine prepared from SFV replicated on monolayer of RK 13 cell line yields at least the same effect as vaccines against rabbit myxomatosis at present produced' abroad.
The replication of virus in a defined standard cell substrate and in a maintenance medium guarantees the preparation of safe and effective vaccine. The use of Earle maintenance medium for virus multiplication and of the same medium or buffered saline as a diluent of lyophilized vaccine is advantageous also from the economical point of view.
By orientation testing on young animals and by experiments on mature rabbits it has been established (Matthes 1978 ) that the vaccine prepared from the SFV is safe for rabbits of various age categories. The subcutaneous vaccination is not followed by postvaccination reactions. This fact confirms the data by Eissner (1966) who found that the immunity was not dependent on the fibroma development at the site of inoculation. In one vaccination dose (equal to 1 ccm) 12.6 --400 PD co is contained.
When vaccination with subsequent revaccination were employed practically 100 % immunity was found four months after the revaccination. Even seven months after revaccination (experiments with longer time period have not been undertaken) the immunity was found to be solid in at least 75 % of vaccinated population. If a single vaccination was effected the same degree of immunity could be expected approximately for three months. It follows from the above stated data that by vaccination with subsequent revaccination using SFT vaccine in spring months a solid immunity in rabbits could be ensured for the rest of the year.
Pousitelnost vim Shopeho fibromu pomnozovaneho na bunecnych kulturach k imunoprofylaxi myxomat6zy kralikit Virus Shopeho fibromu pomnozovany na bunecnych kulturach linie RK 13 je vhodny k priprave lyofilizovane vakciny proti myxomat6ze kraliku, ktera je neskodna a dostatecne ucinna. Po jednorazove podkozni aplikaci vakciny je mozno pocitat se solidni imunitou po dobu tfi mesicu. Po vakcinaci s naslednou revakcinacf [e mozno jeste za sedm mesfcu pocitat se solidni imunitou neimene u 75 0/0 vakcinovane populace. 
